AMCP Submits Comments to Senate Finance Committee on Drug Pricing Bill HHS Announces Action Plan for Safe Importation of Prescription Drugs; CMS Issues 2020 Physician Fee Schedule; AMCP Submits Comments on Reducing Administrative Burdens in Health Care

White House Withdraws ‘Rebate Rule’; House Holds Hearings and Markups on Bills Addressing Drug Pricing Transparency; CMS Issues New Proposed Rule on ePA; CMS Seeks Comments on Reducing Administrative Burdens in Health Care AMCP Takes Steps to Improve Prior Authorization on Processes

Senate Drug Pricing Bill Unveiled; House Passes CREATES Act; AMCP Comments on Biosimilar and Interchangeable Insulin Products; AMCP Comments on Proposed Rule on Information Blocking; CMS Issues RFI on Reducing Administrative Burden to 'Put Patients Over Paperwork'; AMCP’s PA and UM Concepts in Managed Care Pharmacy Is Available in JMCP

Recent House Activities; Eye on the States; Nonproprietary Naming of Biological Products; Interchangeability with Reference Product; Drug Price Transparency in Medicare & Medicaid; PA and UM Concepts in Managed Care Pharmacy

Leg-Reg Briefing April 2019: Eye on Washington; Eye on the States; HHS-OIG Proposed Rule on Removal of Safe Harbor for Rebates

Leg-Reg Briefing March 2019: AMCP Holds Annual Legislative Days; AMCP Comments on Draft Part D Call Letter; FDA Draft Guidance on Naming of Biologics

Leg-Reg Briefing February 2019: Congress Focuses on Pharmaceutical Pricing; States Introduce Bills Affecting Managed Care Pharmacy; Modifying HIPAA Rules to Improve Coordinated Care